Miltefosine for Old World cutaneous leishmaniasis: An experimental study on Leishmania major infected miceFootnote

Peer review under responsibility of Alexandria University Faculty Medicine

Footnote

Available online 21 June 2012

References

• World Health Organization (WHO). Leishmaniasis: disease burden and epidemiological trends. Special Programme for Research and Training in Tropical Diseases. Geneva: WHO; 2002.
   Google Scholar
• P.DesjeuxLeishmaniasis: current situation and new perspectivesComp Immunol Microbiol Infect Dis272004305318
   PubMed Web of Science ®Google Scholar
• M.A.Vannier-SantosA.MartinyW.De SouzaCell biology of Leishmania spp.: invading and evadingCurr Pharm Des82002297318
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). The global burden of disease: update. World Health Organization, Geneva, Switzerland; 2004.
   Google Scholar
• A.C.CunninghamParasitic adaptive mechanisms in infection by LeishmaniaExp Mol Pathol722002132141
   PubMed Web of Science ®Google Scholar
• F.J.Pérez-VictoriaM.P.Sánchez-CañeteK.SeifertS.L.CroftS.SundarS.CastanysMechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical useDrug Resist Updat91–220062639
   PubMed Web of Science ®Google Scholar
• J.ShawThe leishmaniases – survival and expansion in a changing world, a mini-reviewMem Inst Oswaldo Cruz1022007541547
   PubMed Web of Science ®Google Scholar
• M.BoelaertD.Le-rayP.Van-der StuyftHow better drugs could change kala-azar control. Lessons from a cost-effectiveness analysisTrop Med Int Health72002955959
   PubMed Web of Science ®Google Scholar
• R.HadighiP.BoucherA.KhamesipourA.R.MeamarG.RoyM.OuelletteGlucantime-resistant Leishmania tropica isolated from patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugsParasitol Res101200713191322
   PubMed Web of Science ®Google Scholar
• M.K.MittalS.RaiRavinderAshutoshS.GuptaS.SundarN.GoyalCharacterization of natural antimony resistance in Leishmania donovani isolatesAm J Trop Med Hyg762007681688
   PubMed Web of Science ®Google Scholar
• H.A.AhasanM.A.ChowdhuryM.A.AzharA.K.RafiqueuddinK.A.AzadDeaths in visceral leishmaniasis (Kala-azar) during treatmentMed J Malaysia5119962932
   Google Scholar
• E.A.M.FleerC.UngerD.J.KimH.EiblMetabolism of ether phospholipids and analogs in neoplastic cellsLipids221987856861
   PubMed Web of Science ®Google Scholar
• P.HilgardT.KlennerJ.StekarC.UngerAlkylphosphocholines: a new class of membrane active anticancer agentsCancer Chemother Pharmacol3219939095
   PubMed Web of Science ®Google Scholar
• A.KuhlencordT.ManieraH.EiblHexadecylphosphocholine: oral treatment of visceral leishmaniasis in miceAntimicrob Agents Chemother36199216301634
   PubMed Web of Science ®Google Scholar
• S.L.CroftD.SnowdonV.YardleyThe activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma bruceiJ Antimicrob Chemother38199610411047
   PubMed Web of Science ®Google Scholar
• S.SundarTrial of oral miltefosine for visceral leishmaniasisLancet352199818211823
   PubMed Web of Science ®Google Scholar
• C.UngerE.FleerW.DamenzP.HilgardG.NagelH.EiblHexadecylphosphocholine: determination of serum concentrations in ratsJ Lipid Mediat319917178
   PubMedGoogle Scholar
• S.L.CroftG.H.CoombsLeishmaniasis – current chemotherapy and recent advances in the search for novel drugsTrends Parasitol192003502508
   PubMed Web of Science ®Google Scholar
• S.SundarL.P.OlliaroMiltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk managementTher Clin Risk Manag352007733740
   PubMedGoogle Scholar
• S.SundarT.K.JhaC.P.ThakurJ.EngelH.SindermannC.FischerOral miltefosine for Indian visceral leishmaniasisN Engl J Med34722200217391746
   PubMed Web of Science ®Google Scholar
• J.BermanP.LaneTreatment of leishmaniasis with miltefosine: 2008 statusExpert Opin Drug Metab Toxicol49200812091216
   PubMed Web of Science ®Google Scholar
• J.SotoB.A.AranaJ.ToledoN.RizzoJ.C.VegaA.DiazMiltefosine for New World cutaneous leishmaniasisClin Infect Dis389200412661272
   PubMed Web of Science ®Google Scholar
• J.SotoJ.ReaM.BalderramaJ.ToledoP.SotoL.ValdaEfficacy of miltefosine for Bolivian cutaneous leishmaniasisAm J Trop Med Hyg7822008210216
   PubMed Web of Science ®Google Scholar
• A.V.C.FilhoI.C.LucasR.N.R.SampaioComparative study between oral miltefosine and parenteral antimonate of N-methyl glucamine in the treatment of experimental leishmaniasis caused by Leishmania amazonensisRev Soc Bras Med Trop4142008340353
   Web of Science ®Google Scholar
• P.EscobarS.MatusC.MarquesS.L.CroftSensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), Et-18-och3 (eldefosine) and amphotericin BActa Trop8122002151157
   PubMed Web of Science ®Google Scholar
• O.ZerpaM.UlrichB.BlancoM.PolegreA.AvilaN.MatosDiffuse cutaneous leishmaniasis responds to miltefosine but then relapsesJ Dermatol1566200713281335
   Web of Science ®Google Scholar
• Y.KeynanO.E.LariosM.C.WisemanM.PlourdeM.OuelletteE.RubinsteinUse of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from AfghanistanCan J Infect Dis Med Microbiol192008394396
   PubMed Web of Science ®Google Scholar
• P.A.M.Van-ThielT.LeenstraP.A.KagerH.J.De-VriesM.Van-VugtA.BartMiltefosine treatment of Leishmania major infection; an observational study involving Dutch military personnel returning from Northern AfghanistanClin Infect Dis5020108083
   Web of Science ®Google Scholar
• C.McCartry-BurkeP.A.BatesD.M.DwyerLeishmania donovani: use of two different commercially available chemically defined media for the continuous in vitro cultivation of promastigotesExp Parasitol731991385387
   Web of Science ®Google Scholar
• Eissa MM, Amer EI, El-Sawy SMF. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis. Exp Parasitol 2011, in press. http://dx.doi.org/doi:10.1016/j.exppara.05009.
   Google Scholar
• M.P.BarretJ.C.Mott-ramG.H.CommbsRecent advances in identifying and validating drug targets in Trypanosomes and LeishmaniasTrend Microbiol719998288
   PubMed Web of Science ®Google Scholar
• J.D.ChulayA.M.BrycesonQuantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasisAm J Trop Med Hyg3231983475479
   PubMed Web of Science ®Google Scholar
• M.A.HayatPrinciples and techniques of EM: biological application2nd ed1981Pock Press, Union New Jersey University
   Google Scholar
• T.GarnierA.MantylaT.JarvinenJ.LawrenceM.BrownIn vivo studies on the antileishmanial activity of buparvaquone and its prodrugsJ Antimicrob Chemother602007802810
   PubMed Web of Science ®Google Scholar
• T.P.DorloP.P.Van ThielA.D.HuitemaR.J.KeizerH.J.De VriesJ.H.BeijnenPharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patientsAntimicrob Agents Chemother52200828552860
   PubMed Web of Science ®Google Scholar
• M.G.AguiarD.L.SilvaF.A.NunanE.A.NunanA.P.FernandesL.A.M.FernandesCombined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania major leads to reduction in both lesion size and systemic parasite burdensAntimicrob Agents Chemother64200912341240
   Google Scholar
• M.MohebaliA.FoutohiB.HoshmandZ.ZareiB.AkhoundiA.RahnemaComparison of miltefosine and meglumine antimonite for treatment of zoonotic cutaneous leishmaniasis by randomized clinical trial in IranJ Acta Trop103120073340
   PubMed Web of Science ®Google Scholar
• A.SchubachM.C.MavzochiT.Cuzzi-MayaA.V.OliveiraM.L.AraujoA.L.OliveiraCutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cureAm J Trop Med Hyg5861998427824
   Web of Science ®Google Scholar
• R.N.R.SampaioI.C.LucasH.L.TakamiInefficacy of the association N-methyl glucamine and topical miltefosine in the treatment of experimental cutaneous leishmaniasis by Leishmania leishmania amazonensisJ Venom Anim Toxins1332007598606
   Web of Science ®Google Scholar
• M.CalvopinaE.A.GomezH.SindermannP.J.CooperY.HashiguchiRelapse of New World diffuse cutaneous leishmaniasis caused by Leishmania mexicana after miltefosine treatmentAm J Trop Med Hyg756200610741077
   PubMed Web of Science ®Google Scholar
• S.R.OttT.KlennerP.OverathT.AebischerTopical treatment with hexadecylphosphocholine (Miltex®) efficiently reduces parasite burden in experimental cutaneous leishmaniasisTrans R Soc Trop Med Hyg9319998590
   Web of Science ®Google Scholar
• N.K.VermaC.S.DeyPossible mechanism of miltefosine-mediated death of Leishmania donovaniAntimicrob Agents Chemother48200430103015
   PubMed Web of Science ®Google Scholar
• R.S.BrayExperimental leishmaniasis of mammalsW.PetersR.Killick-KendrickThe leishmaniasis in biology and medicine1987Academic PressLondon, Orlando425463
   Google Scholar
• M.M.EissaA.S.SolimanS.O.NassarUltrastructural and immunological features of experimental cutaneous leishmaniasis after treatment with intralesional hypertonic sodium chloride and CO2 laser raysJ Egypt Soc Parasitol3312003329352
   Google Scholar
• M.VenkataramM.MoosaL.DeviHistopathological spectrum in cutaneous leishmaniasis: a study in OmanIndian J Dermatol Venereol Leprol6762001294298
   Google Scholar
• M.M.EissaL.K.YounisE.A.BadawyUltra structure study of experimental cutaneous leishmaniasis before and after dapsone intakeJ Egypt Soc Parasitol2721997539552
   Google Scholar
• C.M.AdadeT.Souto-PadrónContributions of ultrastructural studies to the cell biology of trypanosmatids: targets for anti-parasitic drugsOpen Parasitol J42010178187
   Google Scholar
• T.WiederW.ReutterC.E.OrfanosMechanisms of action of phospholipid analogs as anticancer compoundsProg Lipid Res381999249259
   PubMed Web of Science ®Google Scholar
• M.RybczynskaM.SpitalerN.G.KnebelEffects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivitiesBiochem Pharmacol622001765772
   PubMed Web of Science ®Google Scholar
• M.M.WrightA.G.HoweV.ZarembergCell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analoguesBiochem Cell Biol8220041826
   PubMedGoogle Scholar
• C.C.GeilenT.WiederW.ReutterHexadecylphosphocholine inhibits translocation of CTP: choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cellsJ Biol Chem267199267196724
   Web of Science ®Google Scholar
• F.ÜberallH.OberhuberK.MalyJ.ZaknunL.DemuthH.H.GrunickeHexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activityCancer Res511991807812
   PubMed Web of Science ®Google Scholar
• KlausGriewankCarolineGazeauAndreasEichhornEsthervon StebutMiltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functionsAntimicrob Agents Chemother5422010652659
   PubMed Web of Science ®Google Scholar
• H.LuxD.T.HartP.J.ParkerT.KlennerEther lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for antileishmanial alkyl phospholipids analoguesAdv Exp Med Biol4161996201211
   PubMedGoogle Scholar
• R.M.Santa-RitaA.Henriques-PonsH.S.BarbosaS.L.De-CastroEffect of lysophospholipid analogues; edelfosine, ilmofosine, and miltefosine against Leishmania amazonensisJ Antimicrob Chemother542004704710
   PubMed Web of Science ®Google Scholar
• J.R.Luque-OrtegaL.RivasMiltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotesAntimicrob Agent Chemother514200713271332
   PubMed Web of Science ®Google Scholar